Daniel M. Musher

Prof. Daniel M. Musher

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
JMJoshua P. Metlay
Joshua P. Metlay
GWGrant W. Waterer
Grant W. Waterer
ALAnn C. Long
Ann C. Long
AAAntonio Anzueto
Antonio Anzueto
JBJan Brozek
Jan Brozek
CWCynthia G. Whitney
Cynthia G. Whitney
Background: This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia. Methods: A multidisciplinary panel conducted pragmatic systematic reviews of the relevant research and applied Grading of Recommendations, Assessment, Development, and Evaluation methodology for clinical recommendations. Results: The panel addressed 16 specific areas for recommendations spanning questions of diagnostic testing, determination of site of care, selection of initial empiric antibiotic therapy, and subsequent management decisions. Although some recommendations remain unchanged from the 2007 guideline, the availability of results from new therapeutic trials and epidemiological investigations led to revised recommendations for empiric treatment strategies and additional management decisions. Conclusions: The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia.

16 February 1998 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JWJeffrey N. Weiser
Jeffrey N. Weiser
NPNina Pan
Nina Pan
KMKarin L. McGowan
Karin L. McGowan
DMDaniel M. Musher
Daniel M. Musher
AMAdèle Martin
Adèle Martin
JRJim Richards
Jim Richards
Haemophilus influenzae undergoes phase variation in expression of the phosphorylcholine (ChoP) epitope, a structure present on several invasive pathogens residing in the human respiratory tract. In this study, structural analysis comparing organisms with and without this epitope confirmed that variants differ in the presence of ChoP on the cell surface–exposed outer core of the lipopolysaccharide. During nasopharyngeal carriage in infant rats, there was a gradual selection for H. influenzae variants that express ChoP. In addition, genotypic analysis of the molecular switch that controls phase variation predicted that the ChoP+ phenotype was predominant in H. influenzae in human respiratory tract secretions. However, ChoP+ variants of nontypable H. influenzae were more sensitive to the bactericidal activity of human serum unrelated to the presence of naturally acquired antibody to ChoP. Serum bactericidal activity required the binding of C-reactive protein (CRP) with subsequent activation of complement through the classical pathway. Results of this study suggested that the ability of H. influenzae to vary expression of this unusual bacterial structure may correlate with its ability both to persist on the mucosal surface (ChoP+ phenotype) and to cause invasive infection by evading innate immunity mediated by CRP (ChoP− phenotype).

27 September 2017 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
DMDaniel M. Musher
Daniel M. Musher
MAMichael S Abers
Michael S Abers
JBJohn G Bartlett
John G Bartlett
Before 1945, Streptococcus pneumoniae caused more than 90% of cases of pneumonia in adults. After 1950, the proportion of pneumonia caused by pneumococcus began to decline. Pneumococcus has continued to decline; at present, this organism is identified in fewer than fewer10%–15% of cases. This proportion is higher in Europe, a finding likely related to differences in vaccination practices and smoking. Gram-negative bacilli, Staphylococcus aureus, Chlamydia, Mycoplasma, and Legionella are each identified in 2%–5% of patients with pneumonia who require hospitalization. Viruses are found in 25% of patients, up to one-third of these have bacterial coinfection. Recent studies fail to identify a causative organism in more than 50% of cases, which remains the most important challenge to understanding lower respiratory infection. Our findings have important implications for antibiotic stewardship and should be considered as new policies for empiric pneumonia management are developed.

21 December 2022 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
NGNaomi J. Gadsby
Naomi J. Gadsby
DMDaniel M. Musher
Daniel M. Musher
All modern advances notwithstanding, pneumonia remains a common infection with substantial morbidity and mortality. Understanding of the etiology of pneumonia continues to evolve as new techniques enable identification of already known organisms and as new organisms emerge.

15 February 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
DMDaniel M. Musher
Daniel M. Musher
SMSusan B. Manoff
Susan B. Manoff
CLCharlie Liss
Charlie Liss
RMRichard D. McFetridge
Richard D. McFetridge
RMRocio D. Marchese
Rocio D. Marchese
JSJeffrey L. Silber
Jeffrey L. Silber
Background. This study assessed antibody levels for 5 years after primary vaccination or revaccination with 23-valent pneumococcal polysaccharide vac

18 July 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
BJBarbara E. Jones
Barbara E. Jones
JRJulio A. Ramirez
Julio A. Ramirez
EOEyal Oren
Eyal Oren
Nilam SoniNilam Soni
Nilam Soni
LSLiam R Sullivan
Liam R Sullivan
KWKevin Wilson
Kevin Wilson
Background: Understanding of the diagnosis and treatment of adults with community-acquired pneumonia (CAP) has evolved thanks to new evidence, experience, and emerging technologies. This document updates evidence-based clinical practice guidelines on four key questions for the diagnosis and management of adult patients with CAP. Methods: A multidisciplinary panel integrated systematic reviews of comparative evidence with other relevant research and clinical experience, then applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology to produce recommendations using the Evidence to Decision Framework. Results: The panel formulated clinical recommendations that address questions related to CAP, including lung ultrasound for diagnosis, empiric antibacterial therapy if a test for a respiratory virus is positive, antibiotic duration, and the use of systemic corticosteroids. Conclusions: The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with CAP.